As we covered in an earlier post, the PTAB has instituted two IPR proceedings concerning patents related to Rituxan® (rituximab) (see IPR2015-00417 (U.S. Patent No. 7,976,838) and IPR 2015-00415 (U.S. Patent No. 7,820,161)).
The PTAB had denied institution on a third rituximab IPR petition filed by Boehringer Ingelheim (see IPR2015-00418 (U.S. Patent No. 8,329,172)).
On August 12, 2015, Boehringer Ingelheim filed a request for rehearing on the PTAB’s decision to decline institution of IPR in case No. IPR2015-00418 (U.S. Patent No. 8,329,172).
On August 14th and August 17th, Celltrion, Inc. also filed petitions concerning the same two patents for which IPR was instituted in the Boehringer Ingelheim proceedings, along with motions to join the two instituted IPR proceedings (IPR2015-00417 (U.S. Patent No. 7,976,838) and IPR 2015-00415 (U.S. Patent No. 7,820,161)).
We will continue to track these proceedings and will provide updates here on the Big Molecule Watch (with updated collections of relevant IPR documents in the IPR section of the blog, under “Links” to the right of this page).